We are excited to announce that Joshua Grass has been appointed Chairperson of Glycomine’s Board of Directors. We welcome Josh at this pivotal point in our company’s growth as we continue to build the company, advance our lead drug candidate GLM101 in clinical trials as a disease-modifying treatment for PMM2-CDG, and expand our pipeline of therapies for orphan diseases. We would like to sincerely thank Christopher M. Starr for his vision and leadership as BOD chairperson in building Glycomine to this stage and driving GLM101 from a discovery-stage program to a promising late-stage drug candidate, and we look forward to his continued support as a scientific and clinical advisor. Read the release for more: https://lnkd.in/ghYf8SB5 #RareDisease #RareDiseases #PMM2CDG #clinicaltrials
Glycomine Inc.
生物技术研究
San Carlos，California 2,069 位关注者
We are developing GLM101, a novel substrate replacement therapy for PMM2-CDG, a congenital disorder of glycosylation.
关于我们
Glycomine is developing orphan drugs for serious rare disorders of metabolism and protein misfolding for which no other therapeutic options exist. The company's approach is to use replacement therapies – substrates, enzymes, or proteins – and to target those molecules to clinically relevant cellular compartments. Glycomine’s lead drug candidate, GLM101, is a novel substrate replacement therapy in development to treat phosphomannomutase 2-congenital disorder of glycosylation (PMM2-CDG), a rare disease representing a critical unmet medical need.
- 网站
-
https://glycomine.com/
Glycomine Inc.的外部链接
- 所属行业
- 生物技术研究
- 规模
- 2-10 人
- 总部
- San Carlos，California
- 类型
- 私人持股
地点
-
主要
获取路线
733 Industrial Rd
US，California，San Carlos，94070
Glycomine Inc.员工
动态
-
Glycomine is pleased to share that we have received FDA Fast Track Designation for GLM101, a potential treatment in clinical trials for PMM2-CDG, a rare genetic disorder of glycosylation. Read the release for more: https://lnkd.in/g7xqnkgp #CDGresearch #RareDisease #RareDiseases #FastTrack #PMM2CDG #clinicaltrials
-
-
We're thrilled to announce the publication of two back-to-back studies in the Molecular Genetics and Metabolism special issue on congenital disorders of glycosylation (CDGs), featuring the preclinical characterization of GLM101, Glycomine's lead drug candidate for #PMM2CDG. By leveraging glycomics and glycoproteomics data, our findings highlight the ability of GLM101 to address critical glycosylation defects in PMM2-CDG patient-derived fibroblasts and further support its ongoing clinical development as a potential therapy for PMM2-CDG. Click here for free access to this paper thru September 12th: https://lnkd.in/g-45aeB9 The second paper is available open access: https://lnkd.in/ghiKiqzQ Learn more about GLM101 here: https://lnkd.in/ggu8gfjY #CDGresearch #raredisease #rarediseases #glycosylation #glycoprotein #glycans #glycosylated #glycoresearch?
-
-
We are excited to have presented data at the #RareDiseaseDay2024 Symposium, CDG Scientific and Family Conference showing encouraging efficacy from our ongoing #clinicaltrial of GLM101 in #PMM2CDG.? Read the press release here: ?https://lnkd.in/gJuXvR79 #CDGresearch #rarediseases #raredisease #clinicaltrials #RareDiseaseDay
-
We are excited to announce that the first pediatric patient has been dosed in a Phase 2 clinical study of GLM101, which is in development as the first potential disease-modifying treatment for #PMM2CDG. https://lnkd.in/gtZhSd2W #CDGresearch #rarediseases #raredisease #clinicaltrial #clinicaltrials #glycosylation #glycoprotein #glycans #glycosylated #glycoresearch
-